These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845 [TBL] [Abstract][Full Text] [Related]
24. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340 [TBL] [Abstract][Full Text] [Related]
25. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
26. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. Soo R; Mery L; Bardot A; Kanesvaran R; Keong TC; Pongnikorn D; Prasongsook N; Hutajulu SH; Irawan C; Manan AA; Thiagarajan M; Sripan P; Peters S; Storm H; Bray F; Stahel R ESMO Open; 2022 Oct; 7(5):100560. PubMed ID: 35988454 [TBL] [Abstract][Full Text] [Related]
28. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592 [TBL] [Abstract][Full Text] [Related]
29. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Mizuno T; Yoshida T; Sunami K; Koyama T; Okita N; Kubo T; Sudo K; Shimoi T; Ueno H; Saito E; Katanoda K; Shibata T; Yonemori K; Okusaka T; Boku N; Ohe Y; Hiroshima Y; Ueno M; Kuboki Y; Doi T; Nakamura K; Kohno T; Yatabe Y; Yamamoto N Jpn J Clin Oncol; 2021 Dec; 51(12):1757-1760. PubMed ID: 34622931 [TBL] [Abstract][Full Text] [Related]
30. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer. Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312 [TBL] [Abstract][Full Text] [Related]
31. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency. Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993 [TBL] [Abstract][Full Text] [Related]
32. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. Remon J; Pignataro D; Novello S; Passiglia F Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408 [TBL] [Abstract][Full Text] [Related]
33. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases. Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398 [TBL] [Abstract][Full Text] [Related]
35. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report. Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790 [TBL] [Abstract][Full Text] [Related]
36. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582 [TBL] [Abstract][Full Text] [Related]
37. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung. Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501 [TBL] [Abstract][Full Text] [Related]
38. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia. Mitsudomi T; Tan D; Yang JC; Ahn MJ; Batra U; Cho BC; Cornelio G; Lim T; Mok T; Prabhash K; Reungwetwattana T; Ren SX; Singh N; Toyooka S; Wu YL; Yang PC; Yatabe Y J Thorac Oncol; 2023 Apr; 18(4):436-446. PubMed ID: 36379356 [TBL] [Abstract][Full Text] [Related]
39. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities. Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099 [TBL] [Abstract][Full Text] [Related]
40. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]